Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Locally advanced differentiated thyroid cancer.

Electron Kebebew1, Orlo H Clark

  • 1Department of Surgery, University of California, San Francisco, UCSF/Mount Zion Medical Center, 513 Parnassus, S-343, San Francisco, CA 94143-1674, USA. kebebewe@surgery.ucsf.edu

Surgical Oncology
|August 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRISPR-Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer.

Molecular carcinogenesis·2026
Same author

Workforce growth without reach: National trends in access to high-volume parathyroid surgeons.

Surgery·2026
Same author

Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage.

Endocrine-related cancer·2026
Same author

Utilization of thyroid ultrasound and surgery after glucagon-like peptide-1 receptor agonist prescription.

Surgery·2026
Same author

Dual targeting of BRAF<sup>V600E</sup> and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress.

Journal of experimental & clinical cancer research : CR·2026
Same author

Corrigendum to "Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis" [Cancer Letters 633 (2025) 217990].

Cancer letters·2025

Locally advanced differentiated thyroid cancer (DTC) requires aggressive surgical treatment. Postoperative radioiodine ablation and TSH suppression are crucial for managing residual disease and improving outcomes in these challenging cases.

Area of Science:

  • Oncology
  • Endocrinology
  • Surgical Oncology

Background:

  • Differentiated thyroid cancer (DTC) often has a good prognosis, but locally advanced forms present significant challenges.
  • Locally advanced DTC, accounting for 54-94% of advanced thyroid cancers, frequently involves vital structures like the recurrent laryngeal nerve, trachea, and esophagus.

Purpose of the Study:

  • To outline the primary treatment strategies for locally advanced differentiated thyroid cancer.
  • To emphasize the importance of surgical resection and adjuvant therapies in managing locally advanced DTC.

Main Methods:

  • Review of current treatment paradigms for locally advanced differentiated thyroid cancer.
  • Discussion of surgical approaches, including the goal of curative resection.
  • Emphasis on the role of postoperative radioiodine ablation and external radiotherapy.

Related Experiment Videos

Main Results:

  • Surgical resection is the cornerstone of treatment for locally advanced DTC.
  • Adjuvant therapies, including radioiodine ablation and TSH suppression, are essential post-surgery.
  • External radiotherapy may benefit patients with microscopic or gross residual disease.

Conclusions:

  • Curative surgical resection should be the primary goal in locally advanced DTC, balancing oncologic outcomes with perioperative risks.
  • Multimodal treatment including surgery, radioiodine ablation, and potentially radiotherapy is critical for optimal disease control.